Micofenolato De Mofetilo Accord

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetilo Accord, is an antimetabolite presented as an oral tablet for oral use. It is employed to reduce the risk of organ rejection in transplant recipients and to modulate immune activity in certain autoimmune conditions.

GNH USA supplies Micofenolato De Mofetilo Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mycophenolate Mofetil is an immunosuppressant that acts on lymphocyte proliferation, making it valuable in transplant and graft‑versus‑host disease management. - Renal transplantation: helps prevent acute kidney graft rejection. - Cardiac transplantation: reduces the incidence of early heart transplant rejection. - Liver transplantation: supports prevention of liver graft rejection. - Hematopoietic stem cell transplantation: used to prevent graft‑versus‑host disease.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Vomiting: occasional emesis. - Abdominal pain: cramping or discomfort. - Headache: transient mild headache. - Upper respiratory infections: increased susceptibility.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Anemia: decreased red blood cell count. - Lymphopenia: low lymphocyte levels. - Severe infections: opportunistic or systemic infections. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease.

Before initiating therapy, clinicians should evaluate baseline labs and patient risk factors. - Blood count monitoring: perform regular CBC to detect cytopenias. - Renal function assessment: adjust dosing in impaired kidney function. - Live vaccine avoidance: do not administer live attenuated vaccines during treatment. - Pregnancy considerations: avoid use unless benefits outweigh potential fetal risks. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Mycophenolate Mofetil may interact with several agents, altering efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Cyclosporine: increases mycophenolate exposure, raising toxicity risk. - Tacrolimus: may elevate mycophenolate levels. - Cholestyramine: binds drug and reduces absorption. - Antacids (aluminum or magnesium): decrease oral bioavailability.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor renal function and potassium. - NSAIDs: may worsen renal impairment. - Live vaccines: increased infection risk, require caution. - Antiviral agents (e.g., acyclovir): may require dose adjustment.